Attorney General William Tong is dramatically expanding the scope and raising the profile of the state’s long-running investigation of drug price-fixing.
generic drugs
Posted inJustice
Connecticut alleges massive, routine price-fixing by pharma
Connecticut’s attorney general alleged a far-reaching price-fixing conspiracy by global and U.S. makers of generic drugs Tuesday in a complaint that greatly expands the scope of the lawsuit initiated by his office last year and eventually joined by most other states. “The allegations of our complaint are shocking, and the depth and breadth of the conspiracies alleged are mind-blowing,” Attorney General George Jepsen said.
Posted inHealth, Politics
Trump attempt to rein in drug prices may have limited success
WASHINGTON – The president’s spokesman says Trump still favors a plan to negotiate Medicare prices, but he did not mention it after a recent meeting with pharmaceutical executives, and his plans to speed FDA approval of new drugs may be hampered by his restrictions on new regulations and cuts to the federal workforce.
Posted inHealth, Justice
Connecticut leads 20 states alleging price-fixing in generic drugs
Attorney General George Jepsen’s office is leading a multi-state investigation of generic drug companies that culminated Thursday in a federal price-fixing lawsuit filed in Hartford that complements an unfolding criminal antitrust investigation by the U.S. Department of Justice.
Posted inHealth, Money, Politics
CT lawmakers push back on pharmaceutical issue in TPP
WASHINGTON – As negotiators for a massive Pacific Rim trade pact meet in Maui for a final round of talks, Connecticut lawmakers are pressing for changes they say will keep the price of key medicines affordable for patients who need them overseas and in the United States.
Posted inHealth
Malloy urged protection for pharmaceutical firms in trade pact
WASHINGTON – Gov. Dannel P. Malloy and other elected officials lobbied the Obama administration for a provision in the Trans-Pacific Partnership trade pact that would protect pharmaceutical companies making some of the most cutting-edge and expensive drugs against competitors who want to make cheaper, generic versions of those medicines.